EDITOR-Congenital disorders of glycosylation (CDG) are a heterogeneous group of autosomal recessive multisystemic conditions causing severe central nervous system and multivisceral disorders resulting from impairment of the glycosylation pathway. [1] [2] [3] Two disease causing mechanisms have been identified so far. CDG I is caused by a defect in the assembly of the dolicholpyrophosphate oligosaccharide precursor of N-glycans and its transfer to the peptide chain, while CDG II results from a defect in the processing of N-glycans. 3 CDG I and II have distinct patterns of abnormal glycosylation depending on the reduction of the glycan chain number or its structure. CDG I, the most frequent form, is the result of diVerent enzyme deficiencies: phosphomannomutase (CDG Ia), phosphomannose isomerase (CDG Ib), and glucosyltransferase (CDG Ic). [3] [4] [5] [6] CDG IIa is characterised by a defect in N-acetylglucosaminyltransferase II and only two cases have been reported previously. [7] [8] [9] [10] [11] Here, we report a new case of CDG IIa sharing a number of clinical features with the two previously reported cases and emphasising the clinical differences from CDG I.
A boy was born at term to unrelated, healthy parents after a normal pregnancy and delivery, birth weight 3050 g, length 48 cm, and OFC 35 cm. At 3 months of age, hypotonia, feeding diYculties, and diarrhoea were noted. A milk protein intolerance was suspected and he was put on a milk free formula until the age of 4 years. He was first referred to our genetic unit at 8 years of age because of mental retardation and facial dysmorphism. On examination, he had severe mental retardation with no speech and an unstable gait. Dysmorphic features included fine hair, large ears, a beaked nose with hypoplastic nasal alae, a long philtrum, thin vermilion border of the upper lip, everted lower lip, large teeth, and gum hypertrophy (fig 1) . Long standing feeding diYculties and diarrhoea had resulted in severe growth retardation (height 109.9 cm (−3 SD), weight 20 kg (−2.5 SD), OFC 50.5 cm (−2 SD)). Chromosome analysis was normal and no diagnosis was made at that time. At 11 years of age, dysmorphic features, severe mental retardation, diarrhoea, and growth retardation were still present (height 120.8 cm (−4 SD), weight 23 kg (−2.5 SD), OFC 50.5 cm (−2 SD)). Kyphosis, widely spaced (but not inverted) nipples, and pectus excavatum were also noted. Echocardiography, MRI, and fundoscopy were normal but an electroretinogram was altered with a severe reduction of both cone and rod responses.
Routine laboratory investigations were performed and showed normal serum creatinine, cholesterol, and alkaline phosphatase concentrations but raised ASAT (195 U/l, normal <20 U/l). Coagulation studies were performed before a tooth extraction and showed decreased blood coagulation factors (factor IX 60%, normal 65-160; factor XI 30%, normal 60-160; factor XII 73%, normal 50-160; protein C 30%, normal 70-130; protein S 60%, normal 70-130), abnormal prothrombin time (19 seconds, normal 25 seconds), and activated partial prothromboplastin time (46 seconds, normal 32 ± 8 seconds). The combination of mental retardation, failure to thrive, abnormal electroretinogram, and coagulation abnormalities were highly suggestive of CDG.
Western blot analysis of various serum glycoproteins (transferrin, 1 -antitrypsin, haptoglobin) were performed as previously described 12 13 and showed an abnormal pattern with one single lower band (fig 2A) . Similarly, isoelectric focusing of serum transferrin showed a markedly abnormal pattern corresponding to an increase of the disialotransferrin and a nearly complete absence of hexa-, penta-, and tetrasialotransferrins in the patient ( fig 2B) . These patterns were identical to those previously reported in CDG IIa. 10 Activity of N-acetylglucosaminyltransferase II (MGAT2) was determined at 37°C on cultured skin fibroblasts, according to Tan et al, 9 and was profoundly deficient (1.9 ± 0.4 µmol/g protein/h, control 38.9 ± 2.4 µmol/g protein/h).
Finally, direct sequencing of the coding region for the catalytic domain of the MGAT2 gene identified two distinct point mutations: a missense mutation changing an adenine into a guanine at nt 952 (N318D) and a nonsense mutation at nucleotide 1017 (C339X) leading to a premature stop codon. The father was found to be heterozygous for the N318D mutation and the mother for the C339X mutation.
We report the third observation of CDG IIa in a child with chronic feeding diYculties of early onset, severe mental retardation, and dysmorphic facial features. The two patients reported previously had severe psychomotor retardation with no speech, stereotypic hand washing behaviour, and epilepsy (the last two features were not observed in our case) (table 1). Growth retardation was also consistently observed in all three cases, but major feeding diYculties with chronic diarrhoea were only observed in our case. Dysmorphic features were mentioned in all cases and appeared distinctive with a beaked nose, long philtrum, thin vermilion border of the upper lip, large ears, gum hypertrophy, and thoracic deformity. Ventricular septal defect was observed in 2/3 cases. In one case, MRI showed white matter lesions, 11 but not in the two other cases. Finally, electroretinogram abnormalities aVecting both cones and rods were observed in our case. Although CDG Ia and IIa are both multisystemic disorders with major nervous system involvement, they are also characterised by specific dysmorphic features. Inverted nipples, skin lipodystrophy, peripheral neuropathy, and cerebellar hypoplasia have never been observed in CDG IIa and the psychomotor retardation appears to be more severe.
All the CDG cases share common biological features, namely liver abnormalities and decreased coagulation factors. All cases result from an alteration of the N-glycosylation pathway through distinct mechanisms. In CDG IIa, N-acetylglucosaminyltransferase II deficiency hampers transfer of the N-acetylglucosaminyl residue, the first residue of the antennae, to its substrate. The lack of one glycoprotein antenna causes a molecular weight loss and a reduction in electrical charge. 10 While the mutations identified in our patient are diVerent from those previously reported, they all occur in the C-terminal end of the catalytic domain of the protein. This domain is highly conserved between rat and humans. 9 MGAT2, which is present in the trans Golgi apparatus, appears to be an essential enzymatic step for the biosynthesis of complex Asn linked glycans. The observation of severe multisystemic developmental anomalies in CDG IIa patients is suggestive of a crucial role of complex N-glycans in human development and particularly in the nervous system.
No treatment is available for CDG IIa at present. However, the identification of the enzyme defect and the disease causing gene make prenatal diagnosis feasible in this rare but underdiagnosed autosomal recessive disorder.
Although all types of CDG share common features, the clinical manifestations of CDG IIa diVer from the typical features of CDG I. In two cases (including ours), the diagnosis was fortuitous (coagulation testing) and made only after the age of 8 years. We therefore suggest giving consideration to the diagnosis of CDG IIa when dealing with the association of developmental delay, dysmorphic features, and growth retardation. 1 2 Reports on mutation analysis in TSC show over 300 unique mutations with a varied spectrum. In cases where a mutation can be identified, approximately 80% have a TSC2 mutation and 20% have a TSC1 mutation. All reported TSC1 mutations are small point mutations causing nonsense changes or splice site changes, or small insertions/deletions causing frameshift mutations. In TSC2, the majority (approximately 85%) are small mutations (point mutations causing splice, nonsense, or missense changes, or small insertion/deletions). The remaining 15% of reported TSC2 mutations are large deletions (ranging in size from 1 kb to 1 Mb). Other large rearrangements (inversions, insertions, translocations) have also been reported, but these account for <1% of reported TSC2 mutations (http://zk.bwh.harvard.edu/ts). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Because TSC is often a devastating disorder with a high frequency of sporadic cases, there is significant demand for genetic testing. Much progress has been made in detecting small mutations in TSC1 and TSC2 using a variety of techniques, such as heteroduplex (HD) analysis, single stranded conformation analysis (SSCP), protein truncation test (PTT), denaturing gradient gel electrophoresis (DGGE), and most recently denaturing high performance liquid chromatography (DHPLC).
Figure 2 Pattern of serum transferrin on SDS/PAGE (A) and isoelectric focusing (B) from a control, a CDG Ia reference patient, and the CDG IIa patient.
3 5 6 8-11 13 14 Although it is important for improving the overall mutation detection rate in TSC patients, there has been less eVort to develop new techniques for identifying large deletions in TSC2, which make up a small but significant percentage of TSC2 mutations. Although screening for small mutations is the best initial strategy for detecting mutations in unknown cases, if a small mutation cannot be detected, the next approach should be screening for large TSC2 deletions. Southern blotting is currently the standard approach but unfortunately it has the disadvantage of requiring substantial quantities of DNA. Cytogenetics and fluorescence in situ hybridisation (FISH) are also standard techniques for detecting large deletions, but require either a fresh blood sample or cultured lymphocytes, and have other limitations. Long range PCR is an alternative method which has been used to identify large deletions and chromosome breakpoints in other disorders. [15] [16] [17] [18] The advantage of long range PCR is that it requires only small quantities of genomic DNA and standard PCR reagents. Also, if a mutation is detected by long range PCR, the sequence of the breakpoint fragments can then easily be determined for confirmation, in contrast to Southern blotting.
Here we describe a strategy for detecting large deletions in TSC2 using long range PCR and report six TSC cases with large deletions, all of which have been sequenced. These methods are important for both genetic testing purposes in TSC, and for the analysis of deletion junctions at the sequence level. This information on deletion junction sequences will help elucidate deletion mechanisms and might identify relative hotspots for these events. Furthermore, this long range PCR strategy is easily applied to other genes suspected of having large deletions.
DNA samples were collected from a series of 84 TSC patients who provided informed consent and met diagnostic criteria. 19 A subset of 29 of these patients had no evidence of a small mutation in TSC1 or TSC2 by single exon amplification and mutational screening, and were screened in this study for large deletions in TSC2 using long range PCR. DNA was extracted from white blood cells or EBV transformed lymphoblastoid cell lines using standard methods. An additional six samples suspected of having genomic rearrangements based on Southern blot abnormalities were also screened using long range PCR. Long range PCR primers were designed using the primer design program of the Wisconsin Package (Genetics Computer Group), and chosen to be 22-33 bp in length with melting temperatures of 68-69°C. A series of 16 forward primers and 12 reverse primers were selected and spaced across the TSC2 genomic region (Genbank AC005600) at 2.8-9 kb intervals. Primer sequences and positions are shown in table 1. A series of 19 primer pairs  (fig 1, table 2) were used in standard long range PCR. In addition, long nested multiplex PCR was performed using single forward primers and a series of reverse primers ( fig  1 and fig 2C) . All long PCR reactions were done in a volume of 25 µl using the LA PCR kit (TaKaRa). Each reaction contained 50-250 ng genomic DNA as template, 0.2 µmol/l of all primers, and 400 µmol/l dNTP. PCR cycling was done on a MJ Research PTC-100 thermal cycler for 32 cycles at 94°C for one minute, 98°C for 20 seconds, and 68°C for 15 minutes, followed by a final extension at 72°C for five minutes. Products were analysed on standard 0.8% agarose gels and stained with ethidium bromide. Agarose gels were run slowly (25-35 volts) for 24 hours at room temperature so that the bands of large amplicons (8-10 kb) were sharp. They were examined after electrophoresing for three to five hours and again after 24 hours. At three to five hours, the presence of all amplicons could be observed and the sizes of smaller amplicons (500 bp-2 kb) determined. The 24 hour time point allowed the detection of small (around 1 kb) size diVerences in the larger amplicons.
In cases where there was evidence for a large deletion, the aberrant PCR amplicon generated using long range PCR and containing the deletion was then purified using a Qiagen gel purification column following the manufactur- The deletion junctions of all six cases were sequenced. The region of the junction was narrowed down by a combination of direct sequencing as well as results of short PCR amplification of individual exons. In some cases, amplification of the junctions was repeated using internal primers. Automated sequencing was done using an ABI 377 machine (Perkin Elmer) with Big Dye terminator chemistries (Perkin Elmer). Sequence traces were analysed using Sequencher (Gene Codes).
We have developed a PCR based assay for detecting large deletions in TSC2. Initially, we designed four primer pairs for amplifying all exons of TSC2 in fragments ranging from 7.6-9.8 kb with no overlap (amplicons 1-4 in fig 1, table 2 ). In a pilot study, we analysed a subset of TSC patient samples not yet found to harbour small TSC2 mutations and identified one large deletion (4.5 kb, patient 1). With these four primer pairs, any deletions spanning a primer position would be missed as only the normal allele would amplify. In order to increase the probability of finding all deletions, we designed additional primers for amplifying overlapping segments of the TSC2 gene. Primers were positioned 2.8-9 kb apart over the span of the TSC2 gene in both directions. As all primers had melting temperatures of 68-69°C and all PCR reactions were done using identical cycling conditions (table 1), diVerent combinations of primers could be used to yield overlapping amplicons of diVerent sizes. After testing all primers for PCR, we expanded our assay to included the amplification of a total of 19 overlapping fragments ranging in size from 1.7-11.6 kb ( fig 1, table 2 ). The smaller sized amplicons (1.7-5.5 kb) were included because smaller deletions of 500 bp-1 kb would be more easily detected in smaller amplicons. Because the standard PCR described above would limit the detection of deletions to those ranging in size from 500 bp to 10 kb, we predicted that larger deletions could be identified if each forward primer was combined with a reverse primer far enough away such that amplification would only occur in the presence of a large deletion. Because the extension time for PCR cycling was 15 minutes, we estimated that primers spaced >15 kb apart would not produce an amplicon unless there was a deletion present. Rather than performing up to 12 individual PCR reactions with each forward primer and each diVerent reverse primer, we included multiple reverse primers in nested multiplex reactions with a single forward primer, as illustrated in fig 1. This significantly reduced the number of Exons 1-6 7.9 kb Exons 26-41 9.8 kb PCR reactions per sample, thereby improving the eYciency of the assay and reducing costs. We did a series of 14 nested multiplex reactions on all samples. In this series, a PCR amplification was performed with a single forward primer and a series of two to 12 reverse primers. All forward primers listed in table 1 were used in a nested multiplex reaction except 60883F and 63753F. In each case, the closest reverse primer was positioned >15 kb away to ensure that a PCR product would amplify only if a deletion was present in the TSC2 gene. We tested this long PCR strategy on a subset of a collection of 84 TSC patient samples with unknown mutations which were being investigated for TSC1 and TSC2 mutations. In this collection, 29/84 patients did not have evidence of a small mutation in TSC1 or TSC2 after analysis by DHPLC. 13 20 Four of these samples (patients 1-4) were found to have large deletions using our long PCR assay ( fig  2, table 3 ). In two cases, standard PCR detected a smaller than expected band. In patient 1, using primers 25118F/ 5'UTR and 33058R/intron 6 amplified a 3.4 kb band rather than the expected 7.9 kb band (fig 2A) . In patient 4, primers 55568F/intron25 and 65432R/3'UTR amplified both the normal 9.8 kb band representing the normal allele as well as an 8.4 kb band ( fig 2B) . In the other two cases (patients 2 and 3), nested multiplex reactions using 25118F/5'UTR with five reverse primers (42469R/intron 15, 49637R/exon 20, 54565R/intron 25, 60911R/intron 32, 65432R/3'UTR) amplified aberrant products suggesting a deletion in TSC2 was present ( fig 2C) . In these cases, repeat standard PCR was performed with primers 25118F/5'UTR and 65432R/ 3'UTR which verified the result and determined the size and location of the deletion.
54565R/intron 25, 60911R/intron 32, 65432R/3'UTR) in a long nested multiplex reaction. In this long nested multiplex reaction, an 800 bp amplicon is observed in lane 3 (patient 2) and a 6 kb amplicon in lane 4 (patient 3) as indicated by the arrows. The presence of any band in this reaction indicates that a deletion in TSC2 is present. Normally there is no amplification as shown in lanes 1-2 and 5-8. The faint bands which appear in lanes
To investigate further the usefulness of this strategy, we obtained six TSC samples from another lab (AV) which were suspected of having large deletions or other rearrangements based on Southern blotting results. One of these (patient 5) has been described previously 21 22 and the others were not fully characterised. In this series, two deletions were identified and their sequences determined. In one case, primers 49327F/intron 19 and 54565R/intron 25 amplified both the expected 5.2 kb band as well as a smaller 3.9 kb band suggesting a 1.3 kb deletion (patient 5). In the other case, the nested multiplex reaction using primer 33093F/intron 6 and several reverse primers (49637R/exon 20, 54565R/intron 25, 60911R/intron 32, 65432R/3'UTR, 74454R/3'UTR and 78956R/3'UTR) showed an aberrant 6.4 kb band suggesting a deletion was present. Repeat standard PCR using primers 33093F/intron 6 and 49637R/exon 20 also resulted in a 6.4 kb amplicon consistent with a 10.1 kb deletion (patient 6). Of these six cases, one was suspected to have an insertion and another was subsequently found to have a translocation involving the TSC2 gene, 23 neither of which were detected using long range PCR.
All six deletions were characterised at the sequence level. A combination of short PCR of intervening exons and sequencing was used to narrow down the location of each deletion junction. Sequences of all six deletion junctions are shown in fig 3. In two cases, the deletions occurred within homologous Alu repeats (patient 1 and patient 6). Although Alu mediated recombination has been described in disease causing rearrangements in other disorders, this has not been reported previously for TSC2. In another two cases, there was a 3 bp overlap at the site of the junction, GCA in patient 3 and GGT in patient 5. In patient 2, there was an 11 bp insertion at the junction and 10 of these base pairs (TGCCTTCAGA) are identical to sequence found a few base pairs away in the intron 40 arm of the junction. In the last case (patient 4), there was a 6 bp insertion (GTTTC) at the junction with no apparent homology to either end. These results suggest there are diverse mechanisms causing deletions in the TSC2 gene.
We have developed a useful strategy using long range PCR to identify large deletions ranging in size from 1.3 kb to 39 kb in the TSC2 gene. Because of the known mutation spectrum in TSC, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] it is most appropriate to analyse new samples for small mutations in TSC2 and TSC1 before using this assay. We used our long range PCR assay for mutation analysis in a set of 29/84 samples not found to have small TSC2 or TSC1 mutations by DHPLC or HD analysis of amplified exons. Using the long PCR method, we detected large deletions in 4/84 or 4.8%. This compares with the wide range of reported frequencies for large deletions in the TSC2 gene: 24 of 163 patients (15%) had large deletions when screened by several methods, but only 11 of 163 (7%) would be small enough to be detected by this long PCR method 3 ; 0/140 patients screened by Southern blot analysis 24 ; and two of 88 patients (2%) screened by Southern blot analysis. 25 If these three large studies are combined, 13/391 patients (3.3%) were found to have deletions in the 500 bp to 79 kb range. Thus, we suspect that our method is capable of detecting most deletions that occur between the primers used here. Clearly, it would fail to detect deletions that extend beyond these primers, many of which have been described, 1 as well as translocations, most large insertions, and more complex genomic rearrangements, which appear rare (<1%) in TSC2. 3 23 Another class of deletions that would be missed by this strategy are those that are intermediate in size (50-500 bp), which would often be missed by both single exon amplification strategies and deletion scanning by long range PCR or Southern blot analysis. These have yet to be reported in TSC2.
In this report we provide the first identification of TSC2 deletion junction sequences (fig 3) . Our results suggest that several mechanisms of deletion occur in this gene. In two cases (patients 1 and 6) Alu mediated homologous recombination occurred. Such Alu and LINE mediated rearrangements are well known for many disease genes, 26-32 but have not yet been reported for TSC2. In these two cases, homologous Alu repeats are present in the introns which are inappropriately joined. In patient 1, there are 110 bp of sequence with 88% homology in the region of the recombination. In patient 6, there are 74 bp of homologous sequence with 88% homology flanking the deletion site. Rudiger et al 33 described a 26 bp core sequence (5' -CCTGTAATCCCAGCACTTTGGGAGGC -3') which was at or very close to the junction sites of several Alu mediated LDL receptor gene deletions. Although copies of this 26 bp sequence are found within the introns at these deletions, they are at some distance (>250 bp) from the junction sites so it is not clear whether they played a role in the recombination process. It is also notable that all four introns involved in the Alu mediated deletions in TSC2 contain poly T or poly A tracts or both flanking the Alu repeat, at distances less than 400 bp away. Flanking poly A/T tracts have been identified in Alu mediated deletions in the Fanconi A gene. 34 35 The deletion junctions in the remaining four patients were diverse. There are two cases (patients 3 and 5) in which there is a 3 bp overlap at the junction. A similar 3 bp overlap has also been observed in an globin mutation, but the mechanism for the illegitimate recombination is not well understood. 28 In the last two cases (patients 2 and 4) there are small insertions at the junction. In patient 4, there is a 6 bp insertion (GTTTC) with no homology to either arm of the junction. It is interesting to note that this insertion contains GTT which is commonly found at topoisomerase I cleavage sites. 36 In patient 2, the 10 bp of the 11 bp insertion between intron 1 and intron 40 are identical to a 10 bp (GTGCCTTCAGA) stretch in intron 40 close to the deletion site. In addition, the 11 bp insertion contains CTT which is another sequence commonly found at topoisomerase I cleavage sites. 36 A small insertion at the site of a deletion has also been described in a 20.7 kb factor VIII gene deletion. 16 Defining the deletion junctions of a larger number of TSC2 deletion cases may be helpful, but based upon present observations several mechanisms of deletions occur in TSC2 without a regional hot spot.
The major advantages of this long PCR approach are that it is simple, requires no special reagents or laboratory equipment, and can be performed on small quantities of genomic DNA, which is easily stored for long periods of time. Furthermore, the sequence of the deletion junction can be determined once an aberrant PCR amplicon is generated, to provide final confirmation that a mutation has been detected. Although we detected a deletion as small as 1.3 kb in this study, we suspect that deletions as small as 500 bp could be detected. The largest deletion detected here was 39 kb, but theoretically deletions as large as approximately 70 kb could be detected with the primers reported here. With eVort in designing additional primers, it is possible that larger deletions could be identified using this method.
The disadvantages of this long PCR strategy is that it is not automated and to analyse each sample requires 33 individual PCR reactions. Although any false positive PCR results would quickly be eliminated after sequencing data were obtained, a false negative could go undetected. Because the PCR failure rate can be as high as 20-30%, it is important always to include positive controls in each PCR set. Another disadvantage is that although long PCR might detect some insertions, it would not detect translocations or inversions, none of which appear to be common in TSC2 but have been reported. 3 23 It is likely that many insertions would not be detected because amplification of the shorter normal allele would be favoured during PCR. Although other new methods such as spectral karyotyping, 37 dynamic molecular combing, 38 or quantitative PCR 27 39 may ultimately prove to be more powerful for detecting large deletions and other large rearrangements, they have been used on a limited number of genes and have not been tested in large numbers of samples with unknown mutations. Furthermore, these methods are not widely used and all require access to expensive, specialised equipment.
Although large deletions in the human genome are not as common as single nucleotide polymorphisms, 40 41 they make a significant contribution to deleterious mutations and for some genes are the most frequent mutation type. In Duchenne muscular dystrophy, large deletions account for 65% of mutations. 39 In the Fanconi anaemia group A gene, 40% of mutations identified in a set of 26 patients were large intragenic deletions. 27 It has been reported that large deletions account for 36% of all BRCA1 mutations including two important founder mutations in a Dutch population of breast cancer families in which a BRCA1 mutation was identified. 29 As it is generally diYcult to assay for all possible deletions, it is quite likely that large deletions and other rearrangements may be underreported and may account for a significant percentage of subjects with linkage to certain genes but in which no mutation has been identified. For instance, it has been suggested that large rearrangements may explain a substantial fraction of the 37% of breast/ovarian cancer families which show linkage to the BRCA1 gene but for whom no mutation has been identified. 30 Undetected deletions may contribute to the 20-30% of TSC patients in which no TSC1 or TSC2 mutation can be identified, 3 although there are several other reasons for failure of mutation identification in TSC.
We thank Joon Chung for assistance with sequencing and Edward Jung for technical assistance. We also thank the TSC patients and their families for contributing blood samples or financial support for this project. This work was supported by NIH grants CA71445 (SD), NS 31535 (DK), and the National Tuberous Sclerosis Association. 3 The options are either frequent surveillance or prophylactic surgery. For male mutation carriers, cancer risks are only slightly increased. The oVspring of mutation carriers have a 50% chance of inheriting the gene mutation. The possibility of prenatal genetic diagnosis for "late onset diseases", such as hereditary breast/ovarian cancer, raises complex ethical questions. 4 5 The present study addresses the question to what extent physicians and policy makers working in genetics or oncology may expect requests for prenatal diagnosis and termination of pregnancy because of carriership for BRCA1/BRCA2.
A questionnaire assessing attitudes towards termination of pregnancy if the fetus was found to be a BRCA1/BRCA2 female or a male mutation carrier was answered by 78 subjects (67 women and 11 men) who underwent presymptomatic DNA testing for hereditary breast/ovarian cancer, six months after receiving their test results. Subjects were asked to indicate to what extent they found termination of pregnancy acceptable for themselves. Subjects with and without a desire to have children were included in the study. There were 26 carriers of the BRCA1/BRCA2 mutation (23 females/three males, mean age 36.5) and 52 non-mutation carriers (44 females/eight males, mean age 38.8). The latter group served as a reference group; they cannot transmit the mutation to their oVspring, but are well informed about the implications of hereditary breast/ ovarian cancer.
None of the 26 mutation carriers found termination of pregnancy in the case of a female or a male mutation carrier fetus as acceptable for themselves. A minority of the non-mutation carriers viewed termination of pregnancy as acceptable in the case of a female (14%) or a male mutation carrier fetus (10%, table 1). The diVerences between mutation and non-mutation carriers are significant (p<0.05, Pearson chi-square test, SPSS/PC, release 8.0). Five of the seven non-mutation carriers accepting termination of pregnancy thought this to be acceptable independent of the sex of the mutation carrier child. This is surprising, since the lifetime risk of developing cancer for males with a BRCA1/BRCA2 mutation is not so high. However, the majority of the non-mutation carriers and all the mutation carriers in the present study rejected termination of pregnancy in the case of a child who (1) has a high risk of developing breast or ovarian cancer later in life (a girl) and/or (2) can transmit the gene to his/her oVspring (boy or girl).
The stronger reluctance in mutation carriers than in non-mutation carriers towards terminating a pregnancy of a mutation carrier boy or girl may have several reasons. Firstly, mutation carriers may be more acutely aware of the burdensome emotional implications of terminating a pregnancy because of BRCA1/BRCA2 carriership than nonmutation carriers. Secondly, they may perceive terminating the pregnancy of a mutation carrier child as incompatible with their own existence.
In subjects at risk for autosomal dominant Huntington's disease, the actual demand for prenatal diagnosis and termination of pregnancy is much lower than would be expected based on studies assessing attitudes towards these techniques. 6 7 Prenatal diagnosis and termination of pregnancy for late onset diseases, with decades of healthy life before onset of the disorder, are considered very diYcult choices for parents. In our experience of 500 families at risk for hereditary breast/ovarian cancer seen during the past five years, two requests for prenatal diagnosis were made by recently identified mutation carriers, who wanted to have children in the near future. Considering the few actual requests for prenatal diagnosis for BRCA1/BRCA2, the emotional burden of such a decision, and the general reluctance to terminate a pregnancy of a mutation carrier child (this study), the demand for prenatal diagnosis in hereditary breast/ovarian cancer families is expected to remain low. Genetic counselling of couples considering these highly complex and burdensome options should focus on supporting parents in the decision making process. There are no general rules of wisdom or ethical desirability that could take priority over finding individual solutions and the need to support each couple.
This study is part of a larger study on psychosocial implications of the presymptomatic DNA test for HBOC, which is funded by the Dutch Cancer Society. EDITOR-Noonan syndrome (NS) is an autosomal dominant developmental disorder in which the cardinal features include short stature, typical facies with hypertelorism, ptosis, downward slanting palpebral fissures, and low set, posteriorly rotated ears. In addition, there is a notable cardiac involvement seen in these patients, principally pulmonary valve stenosis and hypertrophic obstructive cardiomyopathy. 1 2 The frequency of NS has been estimated to be between 1:1000-1:2500 live births. 2 3 Using linkage analysis in a large three generation pedigree, we have previously mapped a gene for NS to an interval of more than 6 cM on 12q24 flanked by the markers D12S1637 and NOS1. 4 5 A similar analysis in smaller two generation families showed genetic heterogeneity for this disorder. 4 Despite the relatively high incidence of NS, there appears to be a distinct lack of large families suitable for linkage analysis, possibly resulting from an increase of infertility in males. 6 However, the location of the NS gene has recently been further refined to a 5 cM interval through the identification of additional recombinants in one additional large NS family. 7 No chromosome rearrangements associated with the disease have so far been discovered. In view of this, one approach currently being used to identify the underlying gene responsible for this disorder is examination of candidate genes from within this large region of chromosome 12. We present below the examination of four candidate genes, the precise localisation of three of which, epidermal growth factor receptor pathway substrate-8 (EPS8), decorin (DCN), and myosin light chain 2 (MYL2), had not previously been accurately determined. The fourth, ribosomal protein L6 (RPL6) was known to lie within the NS interval on 12q24. 8 PCR was used to produce gene specific products for FISH (see below) and to produce exonic fragments for SSCP (see below). Sequence information from the cDNA clones of epidermal growth factor receptor pathway substrate-8 (EPS8) and decorin (DCN) were used to design primers for FISH. Primers used were GACAACTAACAGCATCCAGC (DCN-F), GGATTC-CTACTTGCCTTGGA (DCN-R), CTTCCTTAT-TCTTGGTGT (EPS8-F), and CTCGAACTTGGGT-CATTG (EPS8-R). The primers used for SSCP analysis of the MYL2 and RPL6 genes, and for the FISH of MYL2 (exon 4 product) are shown in table 1. Thermocycling parameters were 96°C for five minutes, 35 cycles of 96°C for 30 seconds, 55°C (DCN) or 50°C (EPS8) for 30 seconds, and 72°C for 30 seconds, using 1.5 mmol/l MgCl 2 . The primers for DCN, EPS8, and MYL2 were produced from database sequences. Those for RPL6 were derived from sequences determined by one of the authors.
The subchromosomal localisation of each gene was determined by hybridisation of fluorescently labelled PCR products to metaphase chromosome spreads. 9 PCR products for DCN, EPS8, and MYL2 (exon 4 product) were labelled using the PCR Digoxigenin Probe Synthesis nick translation kit (Boehringer Mannheim). Conditions for hybridisation and immunofluorescent detection were performed according to the manufacturer's instructions.
Primers for SSCP analysis of genomic DNA were designed from intronic sequences such that the entire exon and flanking splice sites could be analysed (table 1) . PCR conditions were optimised for each primer set and are available upon request. Amplified fragments were analysed for SSCP on a 30 × 40 cm gel containing 5% acrylamide, 0.25% bisacrylamide, with and without 10% glycerol in TBE (100 mmol/l Tris, 100 mmol/l boric acid, 2 mmol/l Na 2 EDTA, pH 8.3). Electrophoresis was performed at 30 W and 4°C.
EPS8 is highly conserved between species, 10 is widely expressed during mouse development, 11 and had previously been assigned to 12q24. 10 However, our FISH analysis localised the gene to chromosome 12p13.2 (fig 1) . To confirm this localisation, the EPS8 cDNA was used to screen a chromosome 12 specific cosmid library (Lawrence Livermore National Laboratory, kindly provided by Dr Sue Chamberlain). The positive clones obtained also hybridised to chromosome 12p13, confirming the localisation and exclusion of this gene (fig 1) .
Through its ability to bind extracellular matrix constituents and growth factors, DCN is thought to play an impor- AAGTAATTTGGTATGTGCCTG AGTCAGCTATTTAATTAGGTTC tant role in the remodelling and maintenance of extracellular matrices. 12 13 Two previous studies, both using radiolabelled in situ hybridisation, suggested diVerent localisations for the DCN gene on chromosome 12 at bands 12q21-q22 and 12q23. 14 15 In view of its proposed function, DCN would be an excellent candidate for NS if it mapped within the interval. FISH clearly showed that the DCN gene maps at 12q13.2q proximal to both of the previous locations, and once again can be excluded as a candidate for NS.
While the genes described above were shown to be located outside the NS locus, this was not the case for the MYL2 gene. MYL2 has previously been assigned to chromosome 12q23-q24.3 by in situ hybridisation. 16 Although the precise function of the protein is not understood, MYL2 is known to be critical for the correct regulation of myosin ATPase activity in smooth muscle. 17 The nonmuscle myosin II-B is known to be required for normal development of the mouse heart 18 and an increase in ventricular MYL2 has been observed during myocardial hypertrophy in patients with valvular stenosis. In addition, missense mutations within the MYL2 gene have been identified in patients with a rare variant of cardiac hypertrophy, 17 an intriguing observation in view of the cardiac anomalies associated with NS. As a result of its position and putative function, MYL2 was regarded as a strong candidate gene for NS.
Using a labelled MYL2 gene fragment in conjunction with genomic clones that flank the NS critical interval, we were able to show that the MYL2 gene overlaps the assignment of the NS gene at 12q24 (fig 2) . Sequence information from the MYL2 gene was used to design primers, which were used in SSCP analysis in 22 familial 4 and 44 sporadic NS patients. Primers were designed which flanked each of the seven MYL2 exons including splice sites (table 1) . Three band shifts were detected in these regions (data not shown). However, the same shifts were also seen with a high frequency in normal controls, or the corresponding change in the nucleotide sequence did not lead to an amino acid substitution, indicating that these changes represent normal polymorphisms. Sequencing showed one substitution at codon 44 (ATT to ATC) which does not result in an amino acid change, while the others were the result of variations in a GT repeat immediately 3' to exon 4. The absence of any pathogenic mutations in the coding regions of MYL2 in any NS patients makes it unlikely that this is the causative gene.
In Drosophila, mutations in genes for the ribosomal proteins have been shown to cause the minute phenotype, which includes small body size, diminished fertility, and specific somatic abnormalities. [19] [20] [21] Furthermore, the ribosomal protein genes RPS4X and RPS4Y are discussed as "candidate" genes for Turner syndrome. [22] [23] [24] Turner syndrome and NS have short stature and webbing of the neck as common symptoms. Heart malformations, although of a diVerent type, are also associated with both disorders. The human RPL6 gene is located in the NS critical interval, 8 25 suggesting this gene as a candidate. To check for possible mutations, the six coding exons of the RPL6 gene as well as the preceding exon containing the 5'UTR were screened by SSCP analysis in the same subset of NS patients as used for the MYL2 gene. The primers are shown in table 1. In exon 4, a point mutation was found in two unrelated aVected subjects from small families with only two parents and two sibs. This mutation is predicted to cause the substitution of lysine, residue 139, for an asparagine (Lys139Asn). While the substitution cosegregates with NS in one family, it does not in the second, in which NS does not cosegregate with the critical region on chromosome 12. No mutations were found in the large family with NS linked to 12q24, and the Lys139Asn substitution was also seen in one out of 150 unaVected controls, showing this A to C transversion to be a rare polymorphism. As for MYL2, the analysis suggests that a role for RPL6 in NS is unlikely. Mutations influencing the expression of these genes cannot yet be excluded as being causative for NS.
In summary, as part of a positional candidate cloning strategy to identify a gene for NS, we have examined a number of potentially interesting candidate genes on chromosome 12. Two were excluded by FISH, while two others located within the NS critical interval showed no causative mutations. In the absence of additional recombination events in NS families which can be unequivocally linked to chromosome 12, a screening strategy geared towards the identification of any chromosomal rearrangements within the NS critical interval is currently being used. In conjunction with this approach, the construction of a genomic contig encompassing the entire NS critical interval, and its sequencing, is also in progress.
The first three authors contributed equally to this work. We would like to thank the Birth Defects Foundation and the British Heart Foundation (grant PG/95077) for their support, and the Dutch Heart Foundation for funding HK and MvR. Case 1 is an 11 1 ⁄2 year old female, the first born to healthy, non-consanguineous parents. Her younger male sib is case 2 of this report. She was the term product of a pregnancy complicated by threatened abortion during the first months and by intrauterine growth retardation. Birth weight was 2400 g, length 46 cm, and OFC 31 cm (all below the 3rd centile). Apgar scores were 7 and 9.
Figure 2 FISH using cosmid 91F7 that contains part of the MYL2 gene. The cosmid hybridised in the NS critical region between the YACs 887b9 and 955d8 (shown together as a). A biotinylated 12 satellite probe (ONCOR) was used as a marker for chromosome 12 (b).
She has had feeding problems, failure to thrive, and severe developmental retardation. She walked unassisted at 6 years and she never achieved any language. Metabolic analysis, including amino acidaemia, amino aciduria, MPS screening, and lysosomal and peroxisomal enzymes has been negative.
Sialotransferrin, cholesterol, and 7-dehydrocholesterol were within normal limits. The EEG showed moderate multifocal irritative anomalies, without evidence of clinical seizures. MRI of the brain showed the presence of a large cyst in the septum pellucidum and a cavum vergae. The high resolution karyotype was normal, 46,XX.
Physical examination at 11 1 ⁄2 years showed height 120 cm, weight 23 kg, and head circumference 47 cm (all <<3rd centile). She has severe microcephaly, hypertelorism, a flat nasal bridge, a large nose with a large nasal tip, and anteverted nostrils. The mouth is wide and carp shaped. Both the upper and lower lips are thick and everted, giving a coarse appearance to the lower part of the face (fig 1) . The permanent teeth have not yet erupted and the deciduous teeth are small and have enamel hypoplasia. The hair is coarse and thick but microscopic examination does not show significant changes. Sweating is normal.
She has scoliosis and dorsal kyphosis. Spinal x rays show irregular end plates of the vertebrae and platyspondyly ( fig  2) . On lower limb x ray, there are signs of mild metaphyseal dysplasia as well as epiphyseal hypoplasia and diVuse osteoporosis (fig 3) . The femoral necks and epiphyses are small and dysplastic (fig 4) . Hand x rays show mild brachydactyly, most evident in the distal phalanx of the thumbs, and a retarded bone age.
Case 2 is the 9 year old male sib of case 1. He was born at term after an uneventful pregnancy. Amniocentesis showed a normal male karyotype, 46,XY. Birth weight was 2850 g, length 47 cm, and OFC 33 cm. The child showed severe growth and developmental retardation.
He does not walk yet and does not have any language. His behaviour is characterised by continuous psychomotor agitation and instability. He has had three episodes of generalised seizures at 4 years of age and EEG showed important multifocal anomalies. On barbiturate therapy he has been free of seizures since then. MRI of the brain showed a large cyst in the septum pellucidum and cavum vergae ( fig 5) .
On physical examination, he is small (height 112 cm, weight 12 kg, both <<3rd centile). He has microcephaly (OFC 46 cm, <<3rd centile) and facial dysmorphism identical to that of his sister (fig 1) . Mild brachydactyly with stub thumbs was observed.
Skeletal x ray showed changes of a mild spondylometaphyseal dysplasia with epiphyseal involvement (figs 6 and fig 7 7 ). Abdominal echography was unremarkable and an audiogram was normal. Metabolic analyses were negative and lysosomal enzymes in leucocytes and cultured skin fibroblasts were normal. The high resolution blood karyotype was normal.
The two sibs we have described have a malformation syndrome similar to that observed by Hall and Riggs 1 in six out of 14 sibs born to consanguineous parents. Common clinical findings are severe developmental retardation, short stature, microcephaly, and dysmorphic facial features. All the aVected patients have mild and nonspecific spondyloepiphyseal and metaphyseal changes (table 1) .
We add a few new features to the spectrum of this rare, autosomal recessive condition. These include EEG abnormalities, midline brain defects such as large cysts of the septum pellucidum and enlarged cavum vergae, and abnormal dentition.
Hall and Riggs 1 suggested a metabolic basis for the condition they observed in their patients. Two of the aVected sibs had an unusual pattern of biochemical abnormalities in their cultured fibroblasts consisting of decreased -glucoronidase and increased N-acetyl--glucosaminidase activities. However, these preliminary studies have not been confirmed or detailed in further reports. An extensive work up for metabolic disorders has been carried out in our cases but no inborn error of metabolism was discovered.
The skeletal changes present in our cases as well as those described by Hall and Riggs 1 involve the spine, the metaphyses, and the epiphyses but are milder and diVerent from those observed in the known forms of spondylometaphyseal and spondyloepimetaphyseal dysplasias. 3 4 The facial dysmorphism and the skeletal changes are diVerent from those observed by Hunter 5 in his patients with spondylometaphyseal dysplasia. The dental anomalies present in our probands consist of permanence of the deciduous dentition; the panorex, however, shows the presence of all the germs of the permanent teeth. Hypodontia and conical incisors were the changes observed by Rao et al 6 in two sibs with a unique form of spondyloepimetaphyseal dysplasia.
Identification and description of further cases are needed in order to elucidate the aetiology and pathogenesis of the rare autosomal recessive Hall-Riggs syndrome. Dysmorphic sibs trisomic for the region 6q22.1→6q23.3
EDITOR-Since the initial case of partial trisomy 6q was reported by de Grouchy et al, 1 2 at least 23 additional cases have been published. The majority of these cases represent the abnormal segregation of a balanced parental chromosome translocation. While trisomy 6q patients do have some common characteristics, the inconsistent phenotypic features are usually attributed to an accompanying area of monosomy. Most often the deleted area is the terminal band of the recipient chromosome, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] although longer deletions have also been reported. [14] [15] [16] Only deletion of the short arm of acrocentric chromosomes are without clinical eVect, as these are the nucleolar organiser regions (NOR) containing the ribosomal genes which are present in multiple copies within the genome. Robertsonian translocation carriers, who lack two NORs, are phenotypically normal. Hence, trisomy 6q patients who lack one NOR 2 17-20 can be regarded as cases of "pure" trisomy 6q, together with cases of insertion 21 22 and duplication [23] [24] [25] of 6q material. We report a pair of sibs who carry der(7)ins(7;6)(q21.11;q22.1q23.3)mat, as confirmed by fluorescence in situ hybridisation (FISH). Their phenotypes are compared with other cases of "pure" partial trisomy 6q.
Case 1, the proband (II.3, fig 1) is an ethnic Chinese male. He was born at term, weighing 3345 g, to a 32 year old, gravida 7, para 2 female and a 38 year old male. He was referred aged 7 years because of his dysmorphic features and because he was failing in school. The proband's mother had had four spontaneous first trimester miscarriages before the birth of her four children. There was no known consanguinity or previous history of congenital abnormality in the family, neither was there any history of recurrent spontaneous miscarriages in the parent's sibs.
Physical examination showed central obesity with weight (30 kg) on the 97th centile. Height (124.2 cm) was between the 90th and 97th centile but the head circumference (52 cm) was on the 50th centile. Additional craniofacial dysmorphism consisted of brachycephaly, a flat facial profile, bushy, pointed eyebrows, mild hypertelorism, downward slanting palpebral fissures, a flat nasal bridge 17 Conrad et al 18 Taysi et al 19 Stamberg et al 20 Chen et al 21 Giordino et al 23 Henegariu et al 24 Pierpont with anteverted nares, severe midfacial hypoplasia, and a bow shaped mouth with thick lips. Bilateral clinodactyly was also present. He had noisy breathing and a tendency to mouth breathe. The mother noted that he snored loudly but there were no complaints of daytime somnolence. He had been slow in attaining developmental milestones and was found to be educationally subnormal with an IQ of 50 ± 8. A two dimensional echocardiogram, performed because of the presence of a systolic murmur, was normal. Permission to publish clinical photographs was refused. Case 1 was evaluated for obstructive sleep apnoea (OSA) using standard polysomnography. This showed no significant obstructive apnoea. Sleep eYciency was satisfactory. There was no paradoxical inward rib cage movement during inspiration, desaturations, or bradycardia documented.
Case 2 (II.2, fig 1) is the older sister of case 1. She was also born at term by normal delivery and weighed 3175 g. She was seen at 17 years of age. Her height (155.3 cm) was between the 25th and 50th centile and her weight (40.8 kg) was between the 3rd and 10th centile. She had brachycephaly, a flat facial profile, bushy, pointed eyebrows, mild hypertelorism, a flat nasal bridge with anteverted nares, midfacial hypoplasia, a bow shaped mouth, and bilateral clinodactyly. Her craniofacial features were similar to, but milder than, those of her brother. In comparison to him, she did not have downward slanting palpebral fissures or obesity and had thin lips with a long philtrum. Her secondary sexual development was found to be normal. She did not consent to formal IQ testing but was noted to have been slow in attaining developmental milestones and had left school without academic credits. She did not consent to be photographed.
Peripheral blood lymphocytes were cultured from all available family members using a thymidine synchronisation technique. The father and sib II.4 were 46,XY. The mother's karyotype was interpreted as 46,XX,ins(7;6)(q21.11;q22.1q23.3), which represents a balanced direct insertion of chromosome 6q22.1→6q23.3 into band q21.11 on chromosome 7 (fig 2) . Cases 1 and 2 were found to carry the mother's altered chromosome 7, namely der(7)ins(7;6)(q21.11;q22.1q23.3)mat, in addition to two normal copies of chromosome 6, which represents trisomy for the region 6q22.1→6q23.3. FISH, conducted according to the manufacturer's instructions and performed with a chromosome 6 paint and chromosome 6q telomeric sequences, confirmed the presence of trisomy 6 and the interstitial nature of the insertion (fig 3) .
The external clinical features and karyotype of the 11 previously published cases of "pure" partial trisomy 6q, together with the present cases, are summarised in table 1.
The eight cases on the left hand side (group I) have in common an overlap of the region 6q26→6q27. The five cases on the right hand side of the table (group II) represent varied areas of partial trisomy 6q (fig 4) . The cases comprise nine males and four females. In both our family and those previously described, 21 22 the inherited insertion was maternal in origin. Of the inherited translocations with deletion of ribosomal material, two were paternal 17 18 and three were maternal in origin. 2 19 20 In two cases, 23 25 the observed duplication was de novo and in one case 24 the origin was not able to be determined. All cases, suYciently old to assess, exhibited some form of mental retardation and in all cases the majority of the dysmorphism was craniofacial. Despite the relatively large areas of duplicated genetic material, major organ malformation does not appear to be frequently involved in the partial trisomy 6q syndrome. Only two cases 17 20 died in infancy, both from complications arising from cardiac anomalies; the oldest reported case 21 was 19 years old. Group I cases, with the overlap of 6q26→6q27, are characterised by growth retardation, microcephaly, micrognathia, and a short webbed neck. These features are not often found in the group II cases, which adds weight to 6q26→6q27 being the critical region for this phenotype. This was first suggested by Turleau and de Grouchy 2 and was further defined by Brøndum-Nielsen et al, 25 whose patient lacked duplication of the 6q27 telomeric sequences. Midfacial hypoplasia is observed only in our patients and that of Henegariu et al, 24 which may or may not be related to the common breakpoint at 6q23.3. A sleep study was performed in case 1 to exclude OSA in view of his symptoms (noisy breathing, snoring, poor school performance) and the association between midfacial hypoplasia and obstructive sleep apnoea. 26 Despite the severe midfacial hypoplasia, case 1 did not have OSA.
To our knowledge, trisomy for the region 6q22.1→6q23.3 has not been previously reported. We observed the phenotype to be quite diVerent from that recorded in cases which have an overlap of the 6q26→6q27 region. Traits in common to subjects with diVerent areas of trisomy are probably the result of perturbation of multifactorial gene interaction. The currently known genes for disorders (deafness, argininaemia, cardiomyopathy, and hereditary persistence of fetal haemoglobin), proteins (phospholamban, myristoylated alanine rich protein kinase C substrate, protein L-isoaspartate O-methyltransferase, glucocorticoid regulated kinase, immunodeficiency virus type I enhancer binding protein-2, immune interferon receptor, transcription factor 21, and connective tissue growth factor), and DNA sequences (six-twelve leukaemia A de novo complex chromosomal rearrangement involving chromosomes 2, 3, and 10 associated with microcephaly and early onset spasticity EDITOR-Hereditary spastic paraplegia, spastic paraplegia, or familial spastic paraplegia (HSP, SPG, or FSP) are a heterogeneous group of syndromes characterised by degeneration of corticospinal tracts. Currently, two loci for the X linked recessive type are well established, at Xq28 (SPG1, MIM 312900) 1 and at Xq22 (SPG2, MIM 312920). 2 3 Six loci for the autosomal dominant type have been reported, at 14q12-q23 (SPG3, MIM 182600), 4 at 2p21-p24 (SPG4, MIM 182601), 5 6 at 15q11.1 (SPG6, MIM 600363), 7 at 8q23-q24 (SPG8, MIM 603563), 8 at 10q23.3-q24.1 (SPG9, MIM 601162), 9 and at 12q13 (SPG10, MIM 604187). 10 Two loci for the autosomal recessive type were mapped to 8p12-q13 (SPG5A, MIM 270800) 11 and to 16q24.3 (SPG7, MIM 602783), 12 13 respectively. HSPs are clinically subdivided into pure and complicated forms. The autosomal dominant form can be complicated by dementia and epilepsy.
14 The X linked form can be more severe if combined with ataxia, absent extensor pollicis longus, and involvement of cerebral cortex and optic nerves (SPG1). The complicated autosomal recessive type is rare and is described as microcephaly with spastic quadriplegia (MIM 251280). [15] [16] [17] [18] [19] The fact that familial cases were reported, where no linkage to any of the previously mentioned loci could be found, suggests that additional gene loci for hereditary spastic paraplegia exist. 20 21 The genetic heterogeneity supports the concept of a multitude of diVerent genes responsible for spastic paraplegia. Since, however, a marked clinical similarity is found within HSP families with positive linkage to each of the reported loci, it was proposed that gene products from HSP loci may participate in a common biochemical cascade which, if disturbed, results in axonal degeneration that is most pronounced at the ends of the longest CNS axons. 22 Complex chromosomal rearrangements (CCRs) are defined as any structural rearrangement involving more than two chromosome breaks with exchange of segments between at least two chromosomes. 23 Rearrangements with up to seven derivative chromosomes 24 and 10 breakpoints 25 have been reported. Batanian et al 26 reviewed 100 published CCR cases. The detection and interpretation of CCRs is most eYciently achieved by a combination of classical cytogenetic methods, including high resolution banding techniques and FISH using both whole chromosome painting and band specific probes. 27 Recently, multicolour FISH assays have been developed which allow the identification of cryptic translocations, marker chromosomes, and delineation of complex chromosomal aberrations in a single experiment. Based on cross species colour banding technology, RxFISH combines traditional banding capability with colour classification and allows also the detection of intrachromosomal rearrangements, such as duplications, deletions, insertions, and inversions. 28 The strategy for a detailed characterisation of the chromosomal breakpoints of the CCR involving chromosomes 2, 3, and 10 was based on RxFISH and detailed mapping of single site specific YAC clones selected from the CEPH "MegaYAC" library. We analysed the chromosomal breakpoints in order to narrow down the region for putative candidate genes involved in the phenotype of the patient.
The proband, a 2 1 ⁄2 year old boy with severe psychomotor retardation, is the first child of non-consanguineous parents. At the time of birth, the mother was 28 and the father 31 years old. He was born at 41 weeks of gestation following an uneventful pregnancy. Birth weight was 2480 g and Apgar scores were 8/9/10. During the neonatal period general muscular hypotonia combined with hyperreflexia of the lower limbs and the presence of bilateral Babinski signs was noticed. In the first months of life, two episodes of complicated febrile convulsions (EEG normal) occurred. At 12 months, psychomotor development was classified as markedly delayed on a clinical examination. At this time, microcephaly with a head circumference of 44 cm (−2.4 SD) 29 with normal cranial MRI was recorded. Additional clinical abnormalities, such as epicanthus, a broad nasal root, severe myopia, a strabismus convergens alternans, slightly dysplastic ears with a preauricular fistula on the right side, a sacralporus, and hypopigmented skin were noticed (fig 1) . Cardiac ultrasound and ECG were normal. All standard laboratory parameters were within the normal range as were results of amino acid analysis and of very long chain fatty acid screening. At the age of 16 months, spasticity with lower limb predominance became evident and developed to quadriplegia with preserved but considerably reduced motor function of the left upper extremity. At 26 months, his weight is 12.2 kg (−0.42 SD) and head circumference 47 cm (−1.8 SD). The Babinski sign is present bilaterally. He can sit independently but is still unable to walk. He has good eye contact but his social interactions are poor. He does not show any speech development so far, but apparently understands simple commands. Despite extensive testing, no exogenous causes for the psychomotor retardation and the quadriplegia could be found.
Chromosomes of the proband and his parents were investigated using BrdU synchronised cultures in order to obtain preparations suitable for high resolution analysis. 30 A lymphoblast cell line of the patient was established from whole blood according to standard procedures.
YAC clones and information on positive STS hits were taken from Whitehead YAC contigs. 31 DNA from CEPH "MegaYAC" clones were isolated by pulsed field gel electrophoresis and amplified by using degenerate oligonucleotide primed (DOP)-PCR to generate probes for FISH analysis. 32 RxFISH (Applied Imaging International Ltd), and FISH with a subtelomeric probe from 2q HBSP(Research Genetics) and the human pantelomeric probe (ID labs Inc) were performed on standard metaphase spreads according to the recommendations of the suppliers.
Images were recorded using a Zeiss axiophot microscope equipped with a cooled CCD camera (Photometrics). Digitised images were captured and processed on a CytoVision Ultra workstation (Applied Imaging International Ltd).
Conventional cytogenetic examinations on G banded metaphases of the proband showed a CCR of chromosomes 2, 3, and 10. Using high resolution chromosome banding, the translocation breakpoints were mapped to 2q37.3, 3p22.3, and 10q25.2. Therefore, the karyotype is 46,XY,t(2;3;10)(2pter→2q37.3::10q25.2→10qter;3qter→ 3p22.3::?2pter;10pter→10q25.2::3p22. 3→3pter)de novo. A partial ideogram and high resolution karyotype is shown in fig 2. Analysis of the parental chromosomes did not show any abnormalities.
RxFISH (Applied Imaging International, UK), performed on metaphase spreads of the proband, was used to analyse the whole genome for further inter-and intrachromosomal rearrangements in a single assay. Cytogenetic findings were confirmed by this technique and no further rearrangements have been detected (data not shown).
For a detailed mapping of the chromosomal breakpoints, FISH studies were performed on metaphase preparations using numerous YAC clones from the chromosomal regions 3p22.1-p22.3 and 10q24.3-q25.3, which were selected by searching the genome database (GDB). Results of our FISH analysis are summarised in table 1.
Five of the chromosome 3 YAC clones (720_d_5, 793_g_8, 807_d_1, 938_g_7, 938_h_11) are assigned distal to the breakpoint. However, the more proximal YAC clones 750_d_3 and 802_g_1 show signals on the normal Figure 1 The proband aged 12 months. (2) der (3) der (10) Letterschromosome 3, the der(10), and the der(2) indicating a cryptic insertion of chromosome 3 material into the telomeric region of the long arm of chromosome 2 (fig 3,  above) . Unfortunately, the second breakpoint on chromosome 3 is, according to chromosomal 3 linkage data from GDB, about 3 cM proximal to the other breakpoint mentioned above and apparently maps to a gap between the Whitehead contigs 3.6 and 3.7. The YAC clones 712_a_7 and 758_g_3 gave hybridisation signals proximal to both chromosome 3 breakpoints.
To refine the localisation of the translocation breakpoint on the long arm of chromosome 10, six YAC clones specific for 10q24.3-10q25.3 were used for FISH experiments. Among those clones YAC 806_h_8 was found to span the chromosomal breakpoint since it exhibits signals on chromosome 10, the der(10), as well as the der (2) (fig 3,  below) . Although additional signals on chromosomes 5 and 11 indicate that this YAC is chimeric, this does not aVect the usefulness of this clone. The signal of a subtelomeric probe from 2q (HBSP) is proximal to the inserted chromosome 3 material. However, by using a pantelomeric probe, no interstitial signal on the long arm of the derivative chromosome 2 could be obtained. As expected, a terminal signal of the pantelomeric probe is present on the short arm of the derivative chromosome 3 (data not shown). The karyotype according to ISCN (1995) nomenclature is 46,XY,t(2;3;10)(2pter→2q37.3::10q25.2→ 10qter;3qter→3p22.3::?2pter;10pter→10q25.2::3p22.3→ 3pter).ish t(2;3;10)(2pter→2q37.3::3p22.3::10q25.2→10 qter; 3qter→3p22.3::?2pter;10pter→10q25.2::3p2 2.3→3 pter)(2qter+, 750_d_3+, 802_g_1+,806_h_8+;712_a_7+, pantel+;806_h_8+,750_d_3+,80 2_g_1+,938_h_11+).
In our investigation we used a de novo complex chromosomal translocation which evolved as a consequence of two chromosomal breakage events on chromosome 3 and one on each of chromosomes 10 and 2. The most striking clinical features of the proband, besides the spastic quadriplegia, are microcephaly, psychomotor retardation, and distinct facial dysmorphic signs. Spasticity without detectable brain malformation is a very uncommon finding in patients with chromosomal aberrations. Even if we consider the fact that temporary spasticity is a common finding in microcephalic patients with psychomotor retardation, the clinical similarity, especially to microcephaly with spastic quadriplegia (MIM 251280), strongly suggests that at least one critical gene is aVected by one of the breakpoints of this CCR. An extensive database search for genes already mapped to the chromosomal subbands 2q37.3 and 3p22.3 has shown no potential candidate gene so far, which is likely to be associated with spasticity and related motor neurone syndromes. On the other hand, the breakpoint on chromosome 10 is located near the recently published region for SPG9 (10q23.3-q24.2) and within a chromosomal region (10q23.3-q25.2) which is associated with diVerent neurological disorders, including partial epilepsy at 10q24 (MIM 600512), 33 infantile onset spinocerebellar ataxia with sensory neuropathy between D10S192 and D10S1265 (MIM 271245), 34 and progressive external ophthalmoplegia between D10S198 and D10S562 (MIM 157640). 35 CCRs diagnosed by standard cytogenetic analysis are frequently combined with further cryptic rearrangements, 36 which can only be resolved by a detailed molecular cytogenetic analysis using more sophisticated FISH methods. New techniques such as RxFISH are capable, at a higher level of resolution, of verifying or ruling out major additional rearrangements down to several megabases in a single FISH assay. However, it has to be emphasised that even rearrangements or structural abnormalities occurring between diVerent chromosomes but within bands labelled with the identical colour will not be detected by RxFISH. In practice, only detailed mapping with single site specific YAC clones was suYciently sensitive to show that a tiny fragment of chromosome 3 was translocated to chromosome 2 as well. The interstitial representation of the subtelomeric 2qter probe on the derivative chromosome 2 and the fact that the pantelomeric probe showed no signal in this position but one terminal signal on the short arm of derivative chromosome 3 leads to the conclusion that either the breakpoint at 2q37.3 is precisely located between the subtelomeric and telomeric regions or telomeric repeats have been added by other mechanisms. 37 By using YACs, which were previously assigned to contigs on chromosomes 3 and 10, we were also able to identify clones which cover two and flank one additional region of the chromosomal breakpoints of this CCR. Since one of the four breakpoints is located at the very end of the long arm of chromosome 2, distal even to the subtelomeric FISH probe we used, it is likely that this genomic region is of no relevance to the phenotype of the proband.
All the clinical findings could be the result of a loss or gain of function mutation of a single gene rearranged by one of the translocation events. Alternatively, an as yet unidentified submicroscopic deletion or duplication with partial aneusomy of a single or even several rearranged genes could be responsible for the phenotype. A loss or gain of chromosomal material was not detectable in our FISH analysis although an extremely small submicroscopic deletion, insertion, or duplication cannot be ruled out completely. In previous studies, it was convincingly shown that apparently balanced translocations can provide a very valuable resource for positional cloning of genes of interest. 38 The breakpoint on chromosome 10 is within a chromosomal region associated with several neurological disorders. Well established methods for gene identification or isolation of transcribed sequences, such as direct cDNA selection or exon trapping, could be applied to the isolated YAC DNA as a next step to characterise the altered genomic region, which is most likely responsible for the clinical anomalies found in the proband.
In summary, FISH analysis with band specific probes derived from contigs from chromosomes 3 and 10 showed an unusual cryptic insertion and allowed very detailed characterisation of three out of four breakpoints in this CCR between chromosomes 2, 3, and 10. This CCR strongly suggests that a region of chromosome 10q defined by a single YAC (806_h_8) is likely to contain a gene for early onset paraplegia.
The molecular characterisation and biochemical studies will contribute to a better understanding of the pathogenic mechanism of this important neurological disorder. 
